By: Mike Eaton, CPEG
Powders and bulk solids are the quiet backbone of pharmaceutical manufacturing. From active pharmaceutical ingredients (APIs) to final dosage forms, nearly every drug product depends on the precise blending, granulating, drying, milling, and containment of particulate materials. Consistent control over these processes ensures uniform potency, batch-to-batch repeatability, regulatory compliance, and ultimately, patient safety.
Yet despite how common these processes are, bulk solids handling remains one of the most misunderstood and underestimated engineering challenges.
No two powders behave the same. Even materials that look identical on paper can respond very differently once they enter a processing line. Variations in particle size distribution, bulk density, moisture content, heat sensitivity, and cohesiveness can dramatically alter performance. When these realities are overlooked in the early stages of design, the result is predictable: startup delays, bottlenecks, inconsistent product quality, and costly retrofits.
If process engineers want predictable outcomes, they must start with risk mitigation instead of assumptions.
The Case for Integrated Capabilities
In today’s market, there is no shortage of equipment suppliers. Many build high-quality machines, but fewer can design, manufacture, and test complete process solutions under one roof.
That distinction matters.
Comprehensive lab testing allows multiple processing technologies to be evaluated against real material samples before capital decisions are finalized. Instead of guessing whether a drum dryer will outperform a fluid bed dryer, or whether a paddle blender will minimize degradation better than a ribbon design, engineers can validate those answers with data.
Organizations like Carrier Process Equipment Group (CPEG) emphasize this integrated model: equipment design, engineering, manufacturing, and scaled lab testing in one location. That structure reduces risk and eliminates the fragmentation that often leads to misaligned performance expectations.
Testing is not an added expense. It is protection against downtime.
Material Characteristics: The Foundation of Good Design
Every efficient process begins with understanding the material.
Particle Size Distribution influences flowability, drying rates, chemical reaction efficiency, and equipment sizing. A material with a wide PSD may segregate during conveying. Fine particles may over-dry or create dust control issues. Coarse fractions may require pretreatment or size reduction.
Bulk Density impacts drive horsepower, feeder design, and throughput capacity. A miscalculation here can mean undersized motors or overengineered systems that waste capital.
Moisture Content affects nearly everything, including flow behavior, drying energy requirements, discharge characteristics, and retention time. Real-time moisture monitoring can transform a static system into an adaptive one, allowing operators to maintain product quality despite feed variability.
Skipping this analysis is equivalent to designing blind.
Equipment Selection Is Not Interchangeable
Process engineers face a wide array of options: mixers, blenders, dryers & coolers, size reduction equipment, feeders, conveyors, dust collectors, wet scrubbers, filtration systems, and more.
The right choice depends entirely on the material and the application, not on catalog familiarity.
Lab validation clarifies tradeoffs. It reveals not just what works, but what works best under real process conditions.
Why Testing Is Non-Negotiable in Pharmaceutical Processing
While testing is critical across industries, it becomes essential in pharmaceutical manufacturing.
Pharmaceutical powders demand precise uniformity, strict moisture control, minimal degradation, regulatory compliance, and batch-to-batch repeatability.
In pharma, variability is not an inconvenience. It is a compliance risk.
Testing at lab scale allows engineers to evaluate blending homogeneity, drying kinetics, flow properties, and attrition before scaling to production volumes. More importantly, scalable lab units provide data that can be confidently extrapolated to full production systems.
Scalability is where many pharmaceutical projects struggle. A formulation that blends well in a benchtop mixer may segregate in a production-scale vessel. A drying profile that works in a small oven may create hot spots or overdrying in continuous equipment.
Validated lab testing ensures predictable scale-up from pilot to production, replicable retention times, controlled shear exposure, accurate moisture endpoints, and equipment geometry optimization.
Predictability is the currency of pharmaceutical manufacturing. Testing converts uncertainty into measurable performance data.
Pharmaceutical materials are often sensitive to heat and contamination. Equipment must be designed for cleanability, appropriate surface finishes, and controlled material handling. Testing verifies not only process performance but also product integrity.
In pharmaceutical processing, guessing is not acceptable.
Equipment Design: Where Theory Meets Reality
Even the right equipment can fail if poorly designed.
Material flow is often the most critical factor. Segregation, ratholing, bridging, and uncontrolled flooding can cripple throughput. These issues are preventable, but only if flow properties are understood and incorporated into feeder design, hopper geometry, and drive control strategies.
Material degradation must also be minimized. For sensitive products like pharmaceuticals, selecting paddle designs or open tumble blenders that produce tumbling rather than high-shear agitation can significantly reduce product damage.
Temperature control and retention time must be tightly engineered. Some materials require specific thermal profiles to achieve drying targets or initiate chemical reactions. Equipment with adjustable drive systems and built-in heating zones allows real-time control and process flexibility.
Air pollution control also cannot be ignored. Dust generation is inevitable in bulk solids processing. Baghouses and wet scrubbers must be designed to meet emission standards while maintaining process efficiency.
Engineering discipline, backed by lab validation, prevents reactive troubleshooting later.
Testing Accelerates Return on Investment
The cost of lab testing is minor compared to the cost of downtime, redesign, or missed production targets.
Thorough testing can validate new equipment designs, identify inefficiencies before commissioning, reveal energy optimization opportunities, support process warranties, and accelerate startup timelines.
Facilities like those operated by CPEG simulate real-world operating conditions on a smaller scale using modern diagnostics and computerized data collection. Multiple process steps can be tested in a single visit, giving engineers a comprehensive view of system performance.
Rental equipment programs extend this validation into field environments when materials cannot be easily transported or when real operating conditions must be replicated onsite.
In industries where margins are tight and timelines are aggressive, speed matters. Testing shortens the path from concept to stable production.
The Bottom Line
Bulk solids processing will never be simple. Materials are variable. Equipment options are extensive. Applications are complex, but failure is not inevitable.
The difference between a system that struggles and one that performs predictably lies in early decisions, particularly the commitment to comprehensive material analysis and lab validation.
For pharmaceutical manufacturers, that commitment is even more critical. Scalability, lab-unit validation, and predictable scale-up determine whether a process performs consistently at commercial volume.
The smartest process engineers do not assume their systems will work.
They test them before they go live.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!